Literature DB >> 30261967

Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.

Dimitrios Alexopoulos, Christos Pappas, Danai Sfantou, Ioanna Xanthopoulou, Matthaios Didagelos, Petros Kikas, Antonios Ziakas, Dimitris Tziakas, Haralambos Karvounis, Efstathios Iliodromitis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30261967     DOI： 10.1016/j.jacc.2018.07.041

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  3 in total

1.  Platelet inhibition to target reperfusion injury trial: Rationale and study design.

Authors:  Heerajnarain Bulluck; Mervyn H H Chan; Jennifer A Bryant; Ping Chai; Ashish Chawla; Terrance S Chua; Yiu-Cho Chung; Gao Fei; Hee H Ho; Andrew F W Ho; Andrew J Hoe; Syed S Imran; Chi-Hang Lee; Swee H Lim; Boon W Liew; Patrick L Z Yun; Marcus O E Hock; Valeria Paradies; Matthew T Roe; Lynette Teo; Aaron S Wong; Evelyn Wong; Philip E Wong; Timothy Watson; Mark Y Chan; Jack W Tan; Derek J Hausenloy
Journal:  Clin Cardiol       Date:  2018-12-17       Impact factor: 2.882

2.  Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.

Authors:  Giuseppe Gargiulo; Giovanni Esposito; Marisa Avvedimento; Michael Nagler; Pietro Minuz; Gianluca Campo; Felice Gragnano; Negar Manavifar; Raffaele Piccolo; Matteo Tebaldi; Plinio Cirillo; Lukas Hunziker; Pascal Vranckx; Sergio Leonardi; Dik Heg; Stephan Windecker; Marco Valgimigli
Journal:  Circulation       Date:  2020-06-27       Impact factor: 29.690

Review 3.  Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead.

Authors:  Enrico Fabris; Serge Korjian; Barry S Coller; Jurrien M Ten Berg; Christopher B Granger; C Michael Gibson; Arnoud W J van 't Hof
Journal:  Thromb Haemost       Date:  2021-04-30       Impact factor: 6.681
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.